<SEC-DOCUMENT>0001193125-21-270847.txt : 20210913
<SEC-HEADER>0001193125-21-270847.hdr.sgml : 20210913
<ACCEPTANCE-DATETIME>20210913071133
ACCESSION NUMBER:		0001193125-21-270847
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210907
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210913
DATE AS OF CHANGE:		20210913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		211248605

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d151447d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pstv="http://www.plustherapeutics.com/20210907" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2021-09-07_to_2021-09-07">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-09-07_to_2021-09-07">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-09-07_to_2021-09-07">0001095981</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="pstv-20210907.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-09-07_to_2021-09-07"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-07</xbrli:startDate> <xbrli:endDate>2021-09-07</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-09-07_to_2021-09-07">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Report</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-09-07_to_2021-09-07" format="ixt:datemonthdayyearen">September 7, 2021</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-09-07_to_2021-09-07">PLUS THERAPEUTICS, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-09-07_to_2021-09-07" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-09-07_to_2021-09-07">001-34375</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-09-07_to_2021-09-07">33-0827593</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:100%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-09-07_to_2021-09-07">4200 Marathon Blvd.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2021-09-07_to_2021-09-07">Suite 200</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-09-07_to_2021-09-07">Austin</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-09-07_to_2021-09-07" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-09-07_to_2021-09-07">78756</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices, with zip code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-09-07_to_2021-09-07">(737)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-09-07_to_2021-09-07">255-7194</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-09-07_to_2021-09-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-09-07_to_2021-09-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-09-07_to_2021-09-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-09-07_to_2021-09-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-09-07_to_2021-09-07">Common Stock, par value $0.001</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-09-07_to_2021-09-07">PSTV</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Capital Market</span> </span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-09-07_to_2021-09-07" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Appointment of Norman LaFrance as Chief Medical Officer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On September&#160;13, 2021, Plus Therapeutics, Inc. (the &#8220;Company&#8221;) announced the appointment of Dr.&#160;Norman LaFrance as Chief&#160;Medical&#160;Officer (&#8220;CMO&#8221;) and Senior Vice President of the Company, effective on or around December&#160;8, 2021.&#160;Dr.&#160;LaFrance, age 74, will be responsible for leading and developing clinical development strategy and <span style="white-space:nowrap">hands-on</span> leadership of trials across all phases of development; he will lead the regulatory process with the U.S. Food&#160;&amp; Drug Administration (&#8220;FDA&#8221;) and other global agencies from investigational new drug application (IND) through new drug application (NDA) (or biologics license application (BLA)); and he will lead and build the Company&#8217;s clinical development medical affairs and clinical operations teams. Prior to joining the Company,&#160;Dr.&#160;LaFrance served as Chief Medical Officer and Senior Vice President at Jubilant Pharma Ltd. for over nine years where he was responsible for all Pharma Medical&#160;&amp; Regulatory Affairs activities. Dr.&#160;LaFrance has spent four decades in the pharmaceutical and healthcare industry, academia and medical practice. His background includes strategic planning and management of pharmaceutical development for approval by the FDA as well as clinical and academic experience. In addition, Dr.&#160;LaFrance practiced medicine for 10 years and held academic faculty appointments at Johns Hopkins University School of Medicine in the Departments of Medicine and Radiology and the Department of Radiological Sciences in the Johns Hopkins School of Hygiene and Public Health.&#160;He is double board certified in internal medicine and nuclear medicine.&#160;He is a graduate of the medical school at the University of Arizona and received his bachelor of science and master of engineering degrees in nuclear engineering and science from Rensselaer Polytechnic Institute. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On September&#160;7, 2021, in connection with Dr.&#160;LaFrance&#8217;s appointment as CMO for the Company, the Company entered into an Employment Agreement (the &#8220;LaFrance Employment Agreement&#8221;) with Dr.&#160;LaFrance, effective December&#160;8, 2021. Pursuant to the terms of the LaFrance Employment&#160;Agreement,&#160;Dr.&#160;LaFrance&#160;will receive an initial annual base salary of $440,000&#160;and will be eligible to participate in the&#160;Company&#8217;s benefit and compensation plans.&#160;Dr.&#160;LaFrance&#160;has been assigned an initial annual target bonus of&#160;35% of&#160;his&#160;base salary. Further, in an effort to induce Dr.&#160;LaFrance to accept the offer, Dr.&#160;LaFrance will also receive options to purchase up to 120,000 shares of common stock of the Company, which will have an exercise price per share equal to the fair market value of the common stock on the date of grant and which are expected to vest and become exercisable in monthly installments over the next four years, subject to a <span style="white-space:nowrap">one-year</span> cliff. In addition, it is expected that Dr.&#160;LaFrance will enter into the Company&#8217;s standard form of indemnification agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If Dr.&#160;LaFrance&#8217;s employment is terminated by the Company without cause or if Dr.&#160;LaFrance resigns for good reason (such an event, an &#8220;Involuntary Termination&#8221;), Dr.&#160;LaFrance will receive, among other things, severance in an amount equal to the sum of (i)&#160;twelve multiplied by Dr.&#160;LaFrance&#8217;s monthly base salary as in effect immediately prior to the Involuntary Termination, plus (ii)&#160;an amount equal to Dr.&#160;LaFrance&#8217;s target bonus for the year in which the Involuntary Termination occurs, plus (iii)&#160;to the extent such Involuntary Termination occurs prior to the payment of Dr.&#160;LaFrance&#8217;s annual bonus for the calendar year preceding the date of such Involuntary Termination, the amount of his annual bonus for such completed calendar year, plus (iv)&#160;an amount equal to twelve multiplied by the monthly premium required to pay for continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, for Dr.&#160;LaFrance and his or her eligible dependents who were covered under the Company&#8217;s health plans as of the date of the Involuntary Termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This summary of the LaFrance Employment Agreement is qualified in its entirety by reference to the full text of the LaFrance Employment Agreement, which is included as Exhibit 10.1 hereto and incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">There are no arrangements or understandings between&#160;Dr.&#160;LaFrance&#160;and any other person pursuant to which&#160;he&#160;was selected as an officer, and there are no family relationships between&#160;Dr.&#160;LaFrance&#160;and any of the Company&#8217;s directors or executive officers.&#160;Dr.&#160;LaFrance&#160;has&#160;no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation <span style="white-space:nowrap">S-K.</span> </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosures </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On September&#160;13, 2021, the Company issued a press release announcing the appointment of Dr.&#160;LaFrance as the Company&#8217;s Chief Medical Officer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit <br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d151447dex101.htm">LaFrance Employment Agreement, dated September&#160;7, 2021 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d151447dex991.htm">Press Release Announcing CMO Appointment, dated September&#160;13, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: September&#160;13, 2021 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">PLUS THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc H. Hedrick, M.D.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marc H. Hedrick, M.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Office</p></td></tr>
</table></div>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d151447dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS EMPLOYMENT AGREEMENT (this &#147;<B><I>Agreement</I></B>&#148;) is entered into by and between Plus Therapeutics, Inc., a Delaware
corporation (the &#147;<B><I>Company</I></B>&#148;), and Norman LaFrance, M.D. (&#147;<B><I>Executive</I></B>&#148;), and shall be effective on the Executive&#146;s start date of December&nbsp;8, 2021 (the &#147;<B><I>Effective Date</I></B>&#148;).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms and conditions set
forth in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual promises herein contained, the parties agree to the following:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. As used in this Agreement, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The &#147;<B><I>Acquisition Agreement Date</I></B>&#148; means the first day on which the Company and the acquirer formally or informally
agree on the terms of a transaction which, if consummated, would constitute a Change in Control. Informal agreement need not be legally binding, and can be evidenced by such things as a letter of intent (even if legally <FONT
STYLE="white-space:nowrap">non-binding)</FONT> or taking steps, in reliance on the existence of an informal agreement, in contemplation of the consummation of the Change in Control. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B><I>Cause</I></B>&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Executive&#146;s extended disability (defined as the inability to perform, with reasonable accommodation, the essential functions of
Executive&#146;s position for any one hundred twenty (120)&nbsp;days within any continuous period of one hundred fifty (150)&nbsp;days by reason of physical or mental illness or incapacity); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Executive&#146;s repudiation of his employment or of this Agreement (termination for Good Reason, excepted); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) Executive&#146;s conviction of (or plea of no contest with respect to) a felony, or of a misdemeanor involving moral turpitude, fraud,
misappropriation or embezzlement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Executive&#146;s demonstrable and documented fraud, misappropriation or embezzlement against the
Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Reckless or grossly negligent action which causes, or deliberate action intended to cause, material harm to the Company,
including any misappropriation or unauthorized use of the Company&#146;s property or improper use or disclosure of confidential information (but excluding any good faith exercise of business judgment); </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) Intentional failure to substantially perform material employment duties or directives
(other than following resignation for Good Reason as defined below) if such failure has continued for fifteen (15)&nbsp;days after Executive has been notified in writing by the Company of the nature of the failure to perform (it being understood
that the performance of material duties or directives is satisfied if Executive has reasonable attendance and makes good faith business efforts to perform his duties on behalf of the Company). The Company may not terminate Executive for Cause based
solely upon the operating performance of the Company; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) Chronic absence from work for reasons other than illness, permitted
vacation or resignation for Good Reason as defined below; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that prior to the determination that &#147;Cause&#148; under this
Section&nbsp;1(c) has occurred, the Company shall (A)&nbsp;provide to Executive in writing, in reasonable detail, the reasons for the determination that such &#147;Cause&#148; exists, (B)&nbsp;other than with respect to clause (vi)&nbsp;above which
specifies the applicable period of time for Executive to remedy his or her breach, afford Executive a reasonable opportunity to remedy any such breach, (C)&nbsp;provide Executive an opportunity to be heard prior to the final decision to terminate
Executive&#146;s employment hereunder for such &#147;Cause&#148; and (D)&nbsp;make any decision that such &#147;Cause&#148; exists in good faith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The foregoing definition shall not in any way preclude or restrict the right of the Company or any successor or affiliate thereof to discharge
or dismiss Executive for any other acts or omissions, but such other acts or omissions shall not be deemed, for purposes of this Agreement, to constitute grounds for termination for Cause. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B><I>Change in Control</I></B>&#148; shall have the meaning given to such term in Section&nbsp;2(f) of the Company&#146;s 2020 Stock
Incentive Plan, as in effect on the date hereof; provided that in no event shall an issuance of securities by the Company for financing purposes be deemed a Change in Control for purposes of this Agreement. Notwithstanding the foregoing, to the
extent required by Section&nbsp;409A of the Code, if a Change in Control would give rise to a payment or benefit event with respect to any payment or benefit hereunder that constitutes &#147;nonqualified deferred compensation,&#148; the transaction
or event constituting the Change in Control must also constitute a &#147;change in control event&#148; (as defined in Treasury Regulation <FONT STYLE="white-space:nowrap">&#167;1.409A-3(i)(5))</FONT> in order to give rise to the payment or benefit,
to the extent required by Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as
amended from time to time, and the Treasury Regulations and other interpretive guidance issued thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B><I>Good
Reason</I></B>&#148; means the occurrence of any of the following events or conditions without Executive&#146;s written consent: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) The
Company&#146;s material breach of its obligation to pay Executive the compensation earned for any past service (at the rate which had been stated to be in effect for such period of service); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) a change in Executive&#146;s position with the Company (or successor, affiliate, parent or subsidiary of the Company employing him) which
materially reduces Executive&#146;s duties or stature in the business conducted by the Company; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) a reduction in Executive&#146;s
level of compensation under this Agreement (including base salary and fringe benefits and Target Bonus, but excluding stock-based compensation), provided, however, that a Company-wide reduction of compensation of not more than fifteen percent (15%)
that is also applicable to all of the senior management team of the Company and which continues for less than three (3)&nbsp;months, shall not constitute Good Reason. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive must provide written notice to the Company of the occurrence of any of the foregoing events or
conditions without Executive&#146;s written consent within forty-five (45)&nbsp;days of the occurrence of such event. The Company or any successor or affiliate shall have a period of thirty (30)&nbsp;days to cure such event or condition after
receipt of written notice of such event from Executive. Executive&#146;s termination of employment by reason of resignation from employment with the Company for Good Reason shall be an &#147;Involuntary Termination&#148; only if such termination of
employment occurs within ninety (90)&nbsp;days following the expiration of the foregoing thirty (30)&nbsp;day cure period. Executive&#146;s right to terminate employment for Good Reason shall not be affected by Executive&#146;s incapacity due to
physical or mental illness. Executive&#146;s continued employment shall not constitute consent to, or a waiver of rights with respect to, any circumstance constituting Good Reason herein; provided, that the foregoing time periods shall be complied
with. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B><I>Involuntary Termination</I></B>&#148; means (i)&nbsp;Executive&#146;s termination of employment by reason of
Executive&#146;s discharge by the Company other than for Cause, or (ii)&nbsp;Executive&#146;s termination of employment by reason of Executive&#146;s resignation of employment with the Company for Good Reason. Executive&#146;s termination of
employment by reason of Executive&#146;s death or discharge by the Company following Executive&#146;s extended disability (as defined in Section&nbsp;1(c) above) shall not constitute an Involuntary Termination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B><I>Stock Awards</I></B>&#148; means all stock options, restricted stock and such other awards granted pursuant to the
Company&#146;s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.
<U>Services to Be Rendered.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Duties and Responsibilities</U>. Executive shall serve as Chief Medical Officer of the Company. In
the performance of such duties, Executive shall report directly to the Chief Executive Officer (the &#147;<B><I>CEO</I></B>&#148;) and shall be subject to the direction of the CEO and to such limits upon Executive&#146;s authority as the CEO may
from time to time impose. In the event of the CEO&#146;s incapacity or unavailability, Executive shall be subject to the direction of the Board. Executive hereby consents to serve as an officer (Chief Medical Officer) of the Company and agrees to
reasonably consider requests to serve as an officer or director of a subsidiary or affiliate thereof. Executive will be based in his home office working virtually and will travel to the Company&#146;s headquarters or other places as needed to
fulfill the requirements for the role of Chief Medical Officer. Executive shall be subject to and comply with the policies and procedures generally applicable to employees of the Company to the extent the same are not inconsistent with any term of
this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Exclusive Services</U>. Executive shall be employed by the Company on a full- time basis. Executive shall at all
times faithfully, industriously and to the best of his or her ability, experience and talent perform all of the duties that may be assigned to Executive hereunder and shall devote substantially all of his or her productive time and efforts to the
performance of such duties. Subject to the terms of the Confidentiality and Assignment Agreement referred to in Section&nbsp;5(a), this shall not preclude Executive from devoting time to personal and family investments or serving on community and
civic boards, or participating in industry associations, provided such activities do not interfere with his or her duties to the Company, as determined in good faith by the CEO. Executive agrees that he or she will not join any boards, other than
community and civic boards (which do not interfere with his or her duties to the Company), without the prior approval of the CEO. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Compensation and Benefits</U>. The Company shall pay or provide, as the case may be,
to Executive the compensation and other benefits and rights set forth in this Section&nbsp;3. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Base Salary</U>. The Company shall
pay to Executive a base salary of $440,000 per year, payable in accordance with the Company&#146;s usual pay practices (and in any event no less frequently than monthly). Executive&#146;s base salary shall be subject to review annually by and at the
sole discretion of the Board and may be increased (but not decreased (except to the limited extent contemplated by Section&nbsp;1(f)(iii), above) in their discretion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Bonus</U>. Executive shall participate in any bonus plan that the Board or its designee may approve for similarly situated employees of
the Company. Executive&#146;s target bonus under the Company&#146;s annual bonus plan shall be thirty-five percent (35%) of Executive&#146;s base salary (the &#147;<B><I>Target Bonus</I></B>&#148;) and any bonus paid to the Executive shall be based
upon Executive&#146;s performance during the year for which the bonus is being paid, in light of the corporate goals and objectives established by the compensation committee of the Board. Except as expressly provided in this Agreement or in the
terms of the annual bonus plan, and subject to Section&nbsp;4(b)(ii) below, Executive&#146;s entitlement to receive an earned annual bonus shall be conditioned on Executive&#146;s continued employment with the Company through the date such annual
bonus is paid, however, (i)&nbsp;such annual bonus shall be paid no later than six (6)&nbsp;months after the end of the year, and (ii)&nbsp;such condition of continued employment must be applicable to all members of the Company&#146;s senior
management team. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Benefits</U>. Beginning on the first (1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP>) day of the
calendar month following the Effective Date, Executive shall be entitled to participate in benefits under the Company&#146;s benefit plans and arrangements, including, without limitation, any employee benefit plan or arrangement made available in
the future by the Company to similarly situated employees, subject to and on a basis consistent with the terms, conditions and overall administration of such plans and arrangements. The Company shall have the right to amend or delete any such
benefit plan or arrangement made available by the Company to similarly situated employees and not otherwise specifically provided for herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Expenses</U>. The Company shall reimburse Executive for reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-</FONT></FONT> pocket business expenses incurred in connection with the performance of his or her duties hereunder, subject to such policies as the Company may from time to
time establish and Executive furnishing the Company with evidence in the form of receipts satisfactory to the Company substantiating the claimed expenditures. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Paid Time Off</U>. Executive shall be entitled to four (4)&nbsp;weeks of paid time off (&#147;<B><I>PTO</I></B>&#148;) each year,
increasing over the next five years to five (5)&nbsp;weeks per year at increments of one (1)&nbsp;day per year, which such use is subject to the Company&#146;s PTO policy. The entitled PTO is in addition to the Company&#146;s annual eleven
(11)&nbsp;paid holidays, the list of which is published annually by the Company&#146;s human resources department. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Stock Awards</U>. On the Effective Date and as an inducement to accept employment
from the Company, the Executive will be granted a <FONT STYLE="white-space:nowrap">one-time</FONT> option grant to purchase 120,000 shares of the Company&#146;s stock, which option will be granted at 100% of the fair market value of the
Company&#146;s common stock at the end of business on the Effective Date. The option will vest monthly over four (4)&nbsp;years, with 25% of the option vesting at the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the Effective Date
and the remaining amount vesting monthly over the following 36 months in equal installments, subject to the terms of the Executive&#146;s stock option agreement, in the form attached hereto as <U>Exhibit A</U>. Thereafter, Executive shall be
entitled to participate in any equity or other employee benefit plan that is generally available to similarly situated employees of the Company. Except as otherwise provided in this Agreement, Executive&#146;s participation in and benefits under any
such plan shall be on the terms and subject to the conditions specified in the governing document of the particular plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Stock
Award Acceleration.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) In the event of Executive&#146;s Involuntary Termination, the vesting and/or exercisability of each of
Executive&#146;s outstanding unvested Stock Awards shall be automatically accelerated on the date of Executive&#146;s termination of employment as to the number of Stock Awards that would vest over the twelve (12)&nbsp;month period following the
date of Executive&#146;s termination of employment had Executive remained continuously employed by the Company during such period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii)
In the event of Executive&#146;s Involuntary Termination during the period commencing on the Acquisition Agreement Date and ending on the closing of the resulting Change in Control, in addition to any accelerated vesting and/or exercisability to
which Executive may be entitled pursuant to clause (i)&nbsp;above, the vesting and/or exercisability of any remaining outstanding unvested portions of such Stock Awards shall be automatically accelerated on the later of (A)&nbsp;the date of
Executive&#146;s Involuntary Termination and (B)&nbsp;the date of the Change in Control. In addition, with respect to Stock Awards granted to Executive on or after the Effective Date, such Stock Awards may be exercised by Executive (or
Executive&#146;s legal guardian or legal representative) until the latest of (A)&nbsp;three (3) months after the date of Executive&#146;s Separation from Service, (B)&nbsp;with respect to any portion of the Stock Awards that become exercisable on
the date of a Change in Control pursuant to this Section&nbsp;3(g)(ii), three (3)&nbsp;months after the date of the Change in Control, or (C)&nbsp;such longer period as may be specified in the applicable Stock Award agreement; provided, however,
that in no event shall any Stock Award remain exercisable beyond the original outside expiration date of such Stock Award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) In the
event of a Change in Control, the vesting and/or exercisability of any outstanding unvested portions of such Stock Awards shall be automatically accelerated on the date of such Change in Control, provided that Executive remains in the employ or
service of the Company as of the closing of such Change in Control. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) The vesting pursuant to clauses (i), (ii) and (iii)&nbsp;of this
Section&nbsp;3(g) shall be cumulative. The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any less favorable provision in any agreement or plan regarding such Stock Award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Severance</U>. Executive shall be entitled to receive benefits upon a termination of employment only as set forth in this Section&nbsp;4:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U><FONT STYLE="white-space:nowrap">At-Will</FONT> Employment; Termination</U>. The Company and Executive acknowledge that
Executive&#146;s employment is and shall continue to be <FONT STYLE="white-space:nowrap">at-will,</FONT> as defined under applicable law, and that Executive&#146;s employment with the Company may be terminated by either party at any time for any or
no reason, with or without notice. If Executive&#146;s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided in this Agreement. Executive&#146;s
employment under this Agreement shall be terminated immediately on the death of Executive or the resignation of Executive for Good Reason. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Severance Upon Involuntary Termination</U>. Subject to Sections 4(d) and 9(o) and
Executive&#146;s continued compliance with Section&nbsp;5, if Executive&#146;s employment is Involuntarily Terminated, Executive shall be entitled to receive, in lieu of any severance benefits to which Executive may otherwise be entitled under any
severance plan or program of the Company, the benefits provided below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) the Company shall pay to Executive his or her fully earned but
unpaid base salary, when due, through the date of Executive&#146;s Involuntary Termination at the rate then in effect, all accrued but unused PTO, plus all other amounts or benefits to which Executive is entitled under any compensation, retirement
or benefit plan or practice of the Company at the time of termination in accordance with the terms of such plans or practices, including, without limitation, any continuation of benefits required by COBRA or applicable law; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Executive shall be entitled to receive severance pay in an amount equal to the sum of (A)&nbsp;twelve (12) multiplied by Executive&#146;s
monthly base salary as in effect immediately prior to the date of Executive&#146;s Involuntary Termination, plus (B)&nbsp;an amount equal to Executive&#146;s Target Bonus for the year in which Executive&#146;s Involuntary Termination occurs, plus
(C) to the extent such Involuntary Termination occurs prior to the payment to Executive of his annual bonus for the calendar year preceding the date of such Involuntary Termination, the amount of his annual bonus for such completed calendar year
(which amount for 2021 shall in no event be less than his Target Bonus for such year), plus (D)&nbsp;an amount equal to twelve (12)&nbsp;multiplied by the monthly premium Executive is required to pay for continuation coverage pursuant to the
Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#147;<B><I>COBRA</I></B>&#148;) for Executive and his or her eligible dependents who were covered under the Company&#146;s health plans as of the date of Executive&#146;s
Involuntary Termination (calculated by reference to the premium as of the date of Executive&#146;s Involuntary Termination), which amounts will be payable in a lump sum within ten (10)&nbsp;days following the effective date of Executive&#146;s
Release; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) the vesting acceleration provided under Section&nbsp;3(g) above; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Notwithstanding anything to the contrary in this Section&nbsp;4(b), and subject to Sections 4(d) and 9(o) and Executive&#146;s continued
compliance with Section&nbsp;5, in the event Executive&#146;s Involuntary Termination occurs (A)&nbsp;during the period commencing on the Acquisition Agreement Date and ending on the closing of the resulting Change in Control, or (B)&nbsp;within
twelve (12) months following a Change in Control, (1)&nbsp;the references to twelve (12)&nbsp;months in clause (ii) above shall be increased to eighteen (18)&nbsp;months, and (2)&nbsp;Executive&#146;s monthly base salary for purposes of clause
(ii)(A) above shall be equal to the greater of (x)&nbsp;Executive&#146;s monthly base salary as in effect immediately prior to the date of Executive&#146;s Involuntary Termination, or (y)&nbsp;Executive&#146;s monthly base salary as of the
Acquisition Agreement Date, which amounts, to the extent in excess of the amounts to be paid to Executive as a result of his Involuntary Termination pursuant to clause (ii)&nbsp;above, shall be payable in a lump sum within ten (10)&nbsp;days
following the later of (A)&nbsp;the effective date of Executive&#146;s Release and (B)&nbsp;the date of the Change in Control. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Termination for Cause or Voluntary Resignation Without Good Reason</U>. In the event
of Executive&#146;s termination of employment as a result of Executive&#146;s discharge by the Company for Cause, Executive&#146;s resignation without Good Reason, or Executive&#146;s death or termination of employment by reason of discharge by the
Company following Executive&#146;s extended disability (as defined in Section&nbsp;1(c) above), the Company shall not have any other or further obligations to Executive under this Agreement (including any financial obligations) except that Executive
shall be entitled to receive (i)&nbsp;Executive&#146;s fully earned but unpaid base salary, through the date of termination at the rate then in effect, (ii)&nbsp;all accrued but unused PTO, and (iii)&nbsp;all other amounts or benefits to which
Executive is entitled under any compensation, retirement or benefit plan or practice of the Company at the time of termination in accordance with the terms of such plans or practices, including, without limitation, any continuation of benefits
required by COBRA or applicable law. In addition, the vesting of Executive&#146;s unvested Stock Awards previously granted to him or her by the Company shall thereupon cease and none of such unvested Stock Awards shall be exercisable following the
date of such termination. The foregoing shall be in addition to, and not in lieu of, any and all other rights and remedies which may be available to the Company under the circumstances, whether at law or in equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) <U>Release</U>. As a condition to Executive&#146;s receipt of any post-termination benefits pursuant to Section&nbsp;4(b) above, Executive
shall execute and not revoke a general release of all claims in favor of the Company (the &#147;<B><I>Release</I></B>&#148;) in the form attached hereto as <U>Exhibit B</U>. In the event the Release does not become effective within the thirty
(30)&nbsp;day period following the date of Executive&#146;s termination of employment, Executive shall not be entitled to the aforesaid payments and benefits. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Exclusive Remedy</U>. Except as otherwise expressly required by law (e.g., COBRA) or as specifically provided herein, all of
Executive&#146;s rights to salary, severance, benefits, bonuses and other amounts hereunder (if any) accruing after the termination of Executive&#146;s employment shall cease upon such termination. In the event of Executive&#146;s termination of
employment with the Company, Executive&#146;s sole remedy shall be to receive the payments and benefits described in this Section&nbsp;4. In addition, Executive acknowledges and agrees that he or she is not entitled to any reimbursement by the
Company for any taxes payable by Executive as a result of the payments and benefits received by Executive pursuant to this Section&nbsp;4, including, without limitation, any excise tax imposed by Section&nbsp;4999 of the Code. Any payments made to
Executive under this Section&nbsp;4 shall be inclusive of any amounts or benefits to which Executive may be entitled pursuant to the Worker Adjustment and Retraining Notification Act, 29 U.S.C. Sections 2101 et seq., and the Department of Labor
regulations thereunder, or any similar statute. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>No Mitigation</U>. Executive shall not be required to mitigate the amount of any
payment provided for in this Section&nbsp;4 by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Section&nbsp;4 be reduced by any compensation earned by Executive as the result of employment
by another employer or self- employment or by retirement benefits; <U>provided</U>, <U>however</U>, that loans, advances or other amounts owed by Executive to the Company may be offset by the Company against amounts payable to Executive under this
Section&nbsp;4. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Return of the Company&#146;s Property</U>. In the event of Executive&#146;s
termination of employment for any reason, the Company shall have the right, at its option, to require Executive to vacate his or her offices prior to or on the effective date of separation and to cease all activities on the Company&#146;s behalf.
Upon Executive&#146;s termination of employment in any manner, as a condition to Executive&#146;s receipt of any severance benefits described in this Agreement, Executive shall immediately surrender to the Company all lists, books and records of the
Company&#146;s business, and all copies or abstracts thereof, and all other property belonging to the Company, it being distinctly understood that all such lists, books and records, copies and other property, are the property of the Company.
Executive shall deliver to the Company a signed statement certifying compliance with this Section&nbsp;4(g) prior to the receipt of any severance benefits described in this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain Covenants</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Proprietary Information</U>. Executive and the Company have entered into the Company&#146;s standard employee confidentiality and assignment agreement (the &#147;<B><I>Employee Confidentiality and Assignment Agreement</I></B>&#148;). Executive
agrees to perform each and every obligation of Executive therein contained. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Rights and Remedies Upon Breach</U>. If Executive
breaches any of the provisions of this Section&nbsp;5 (the &#147;<B><I>Restrictive Covenants</I></B>&#148;), the Company shall have, in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity,
the right to immediately cease all payments and benefits under Section&nbsp;4(b) above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Whistleblower Provision</U>. Nothing herein
shall be construed to prohibit Executive from communicating directly with, cooperating with, or providing information to, any government regulator, including, but not limited to, the U.S. Securities and Exchange Commission, the U.S. Commodity
Futures Trading Commission, or the U.S. Department of Justice. Executive acknowledges that the Company has provided Executive with the following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act:
(i)&nbsp;Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary information of the Company that is made in confidence to a Federal, State, or local government official
or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, (ii)&nbsp;Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary
information of the Company that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (iii)&nbsp;if Executive files a lawsuit for retaliation by the Company for reporting a suspected
violation of law, Executive may disclose the proprietary information to his attorney and use the proprietary information in the court proceeding, if Executive files any document containing the proprietary information under seal, and does not
disclose the proprietary information, except pursuant to court order. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Insurance; Indemnification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) <U>Insurance</U>. The Company shall have the right to take out life, health, accident,
<FONT STYLE="white-space:nowrap">&#147;key-man&#148;</FONT> or other insurance covering Executive, in the name of the Company and at the Company&#146;s expense in any amount deemed appropriate by the Company. Executive shall assist the Company in
obtaining such insurance, including, without limitation, submitting to any required examinations and providing information and data required by insurance companies. If the Executive&#146;s employment is terminated for any reason other than death,
the Company shall endeavor to assist the Executive to purchase any such life or <FONT STYLE="white-space:nowrap">key-man</FONT> insurance policy then maintained on Executive&#146;s life by the Company (excluding life insurance coverage maintained
under a group policy included in the Company&#146;s standard benefits) for a purchase price equal to its &#147;fair market value&#148; on the date Executive&#146;s employment is terminated. The Executive shall exercise such purchase right within
thirty (30)&nbsp;days after such termination of employment by written notice to the Company and by tendering the purchase price of such policy, in cash, to the Company or the insurer, as required. The fair market value of any such policy shall be
determined in a manner consistent with the Internal Revenue Service&#146;s rules and procedures. If Executive declines or fails to exercise such right of purchase, the Company covenants to retain, and promptly terminate, such policy. </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Indemnification</U>. Executive will be provided with indemnification by the Company
against third party claims related to his or her work for the Company to the extent allowed by Delaware law. The Company shall provide Executive with directors and officers liability insurance coverage at least as favorable as that which the Company
may maintain from time to time for members of the Board and other executive officers. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Arbitration</U>. Except as prohibited by law,
any legal dispute between the Executive and the Company (or between the Executive and any affiliate of the Company, each of whom is hereby designated a third party beneficiary of this Agreement regarding arbitration) arising out of the
Executive&#146;s employment or cessation of employment, or arising out of the Executive&#146;s directorship or resignation from his director position, or this Agreement (a &#147;Dispute&#148;) will be resolved through binding arbitration in Dallas,
Texas, under the rules and procedures of the Texas General Arbitration Act, Texas Civil Practices and Remedies Code, Section&nbsp;171.001 et seq., and pursuant to Texas law. Nothing in this arbitration provision is intended to limit the
Executive&#146;s right to file a charge with or obtain relief from the National Labor Relations Board. THE PARTIES UNDERSTAND THAT BY AGREEING TO ARBITRATE DISPUTES THEY ARE WAIVING ANY RIGHT THEY MIGHT OTHERWISE HAVE TO A JURY TRIAL. This
arbitration provision is not intended to modify or limit substantive rights or the remedies available to the parties, including the right to seek interim relief, such as injunction or attachment, through judicial process, which shall not be deemed a
waiver of the right to demand and obtain arbitration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>General Relationship</U>. Executive shall be considered an employee of the
Company within the meaning of all federal, state and local laws and regulations including, but not limited to, laws and regulations governing unemployment insurance, workers&#146; compensation, industrial accident, labor and taxes. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)
<U>Modification; Prior Claims</U>. This Agreement and the Employee Confidentiality and Assignment Agreement set forth the entire understanding of the parties with respect to the subject matter hereof, and supersede all existing agreements between
them concerning such subject matter, including, without limitation, any employment agreement or offer letter executed by the Company and Executive in effect prior to the Effective Date. This Agreement may be amended or modified only with the written
consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever. For the avoidance of doubt, Stock Awards granted to Employee are outside the scope
of this clause. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) <U>Assignment; Assumption by Successor</U>. The rights of the Company under this Agreement may, without the consent of
Executive, be assigned by the Company, in its sole and unfettered discretion, to any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly, acquires all or
substantially all of the assets or business of the Company. The Company will require any successor (whether direct or indirect, by purchase, merger or otherwise) to all or substantially all of the business or assets of the Company expressly to
assume and to agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place; provided, however, that no such assumption shall relieve the Company of
its obligations hereunder. As used in this Agreement, the &#147;<U>Company</U>&#148; shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement by
operation of law or otherwise. </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) <U>Survival</U>. The covenants, agreements, representations and warranties contained in
or made in Sections 3(g), 4, 5, 6, 7 and 9 of this Agreement shall survive any Executive&#146;s termination of employment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)
<U>Third-Party Beneficiaries</U>. This Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement. For the avoidance of doubt, Employee&#146;s executors, conservators,
guardians and other legal representatives, if any, shall have such rights as conferred by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) <U>Waiver</U>. The failure of either
party hereto at any time to enforce performance by the other party of any provision of this Agreement shall in no way affect such party&#146;s rights thereafter to enforce the same, nor shall the waiver by either party of any breach of any provision
hereof be deemed to be a waiver by such party of any other breach of the same or any other provision hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) <U>Section Headings</U>.
The headings of the several sections in this Agreement are inserted solely for the convenience of the parties and are not a part of and are not intended to govern, limit or aid in the construction of any term or provision hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) <U>Notices</U>. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed
given as indicated: (i)&nbsp;by personal delivery when delivered personally; (ii)&nbsp;by overnight courier upon written verification of receipt; (iii) by email, telecopy or facsimile transmission upon acknowledgment of receipt of electronic
transmission; or (iv)&nbsp;by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to Executive at the address listed on the Company&#146;s personnel records and to the Company at its principal
place of business, or such other address as either party may specify in writing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. All Sections, clauses and
covenants contained in this Agreement are severable, and in the event any of them shall be held to be invalid by any court, this Agreement shall be interpreted as if such invalid Sections, clauses or covenants were not contained herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Governing Law and Venue</U>. This Agreement is to be governed by and construed in accordance with the laws of the State of Texas
applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Except as provided in Sections 5 and 7, any suit brought hereon shall be brought in the state or federal
courts sitting in Travis County, Texas, the parties hereto hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to
service of process in any manner authorized by Texas law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) <U><FONT STYLE="white-space:nowrap">Non-transferability</FONT> of Interest</U>. Subject
to Section&nbsp;9(d), none of the rights of Executive to receive any form of compensation payable pursuant to this Agreement shall be assignable or transferable except through a testamentary disposition or by the laws of descent and distribution
upon the death of Executive. Any attempted assignment, transfer, conveyance, or other disposition (other than as aforesaid) of any interest in the rights of Executive to receive any form of compensation to be made by the Company pursuant to this
Agreement shall be void. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) <U>Gender</U>. Where the context so requires, the use of the masculine gender shall include the feminine
and/or neuter genders and the singular shall include the plural, and vice versa, and the word &#147;person&#148; shall include any corporation, firm, partnership or other form of association. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) <U>Counterparts; Facsimile or .pdf Signatures</U>. This Agreement may be executed in any number of counterparts, each of which when so
executed and delivered shall be deemed an original, and all of which together shall constitute one and the same agreement. This Agreement may be executed and delivered by facsimile or by .pdf file and upon such delivery the facsimile or .pdf
signature will be deemed to have the same effect as if the original signature had been delivered to the other party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)
<U>Construction</U>. The language in all parts of this Agreement shall in all cases be construed simply, according to its fair meaning, and not strictly for or against any of the parties hereto. Without limitation, there shall be no presumption
against any party on the ground that such party was responsible for drafting this Agreement or any part thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) <U>Withholding and
other Deductions</U>. All compensation payable to Executive hereunder shall be subject to such deductions as the Company is from time to time required to make pursuant to law, governmental regulation or order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) <U>Code Section</U><U></U><U>&nbsp;409A</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) This Agreement is not intended to provide for any deferral of compensation subject to Section&nbsp;409A of the Code, and, accordingly, the
severance payments payable under Sections 4(b)(ii) and (iv)&nbsp;shall be paid no later than the later of: (A)&nbsp;the fifteenth (15th) day of the third month following Executive&#146;s first taxable year in which such amounts are no longer subject
to a substantial risk of forfeiture, and (B)&nbsp;the fifteenth (15th) day of the third month following first taxable year of the Company in which such amounts are is no longer subject to substantial risk of forfeiture, as determined in accordance
with Code Section&nbsp;409A and any Treasury Regulations and other guidance issued thereunder. To the extent applicable, this Agreement shall be interpreted in accordance with Code Section&nbsp;409A and Department of Treasury regulations and other
interpretive guidance issued thereunder. Each series of installment payments made under this Agreement is hereby designated as a series of &#147;separate payments&#148; within the meaning of Section&nbsp;409A of the Code. </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Notwithstanding anything herein to the contrary, to the extent any payments to
Executive pursuant to Section&nbsp;4(b)) are treated as <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation subject to Section&nbsp;409A of the Code, then (A)&nbsp;no amount shall be payable pursuant to such section unless
Executive&#146;s termination of employment constitutes a &#147;separation from service&#148; with the Company (as such term is defined in Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> and any successor
provision thereto) (a &#147;<B><I>Separation from Service</I></B>&#148;), (B) any such payment payable under Section&nbsp;4(b)(ii) or (iv)&nbsp;shall be paid on the sixtieth (60th) day following (1)&nbsp;Executive&#146;s Separation from Service
(with respect to payments pursuant to Section&nbsp;4(b)(ii) or (2)&nbsp;the later of Executive&#146;s Separation from Service or the date of the Change in Control, as applicable (with respect to payments pursuant to Section&nbsp;4(b)(iv)), and
(C)&nbsp;if Executive, at the time of his or her Separation from Service, is determined by the Company to be a &#147;specified employee&#148; for purposes of Section&nbsp;409A(a)(2)(B)(i) of the Code and the Company determines that delayed
commencement of any portion of the termination benefits payable to Executive pursuant to this Agreement is required in order to avoid a prohibited distribution under Section&nbsp;409A(a)(2)(B)(i) of the Code (any such delayed commencement, a
&#147;<B><I>Payment Delay</I></B>&#148;), then such portion of Executive&#146;s termination benefits described in Section&nbsp;4(b) shall not be provided to Executive prior to the earlier of (A)&nbsp;the expiration of the <FONT
STYLE="white-space:nowrap">six-month</FONT> period measured from the date of Executive&#146;s Separation from Service, (B)&nbsp;the date of Executive&#146;s death or (C)&nbsp;such earlier date as is permitted under Section&nbsp;409A. Upon the
expiration of the applicable Code Section&nbsp;409A(a)(2)(B)(i) deferral period, all payments deferred pursuant to a Payment Delay shall be paid in a lump sum to Executive within ten (10)&nbsp;days following such expiration, and any remaining
payments due under the Agreement shall be paid as otherwise provided herein. The determination of whether Executive is a &#147;specified employee&#148; for purposes of Section&nbsp;409A(a)(2)(B)(i) of the Code as of the time of his or her Separation
from Service shall made by the Company in accordance with the terms of Section&nbsp;409A of the Code and applicable guidance thereunder (including without limitation Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(i)</FONT> and any successor provision thereto). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) To the extent applicable, this
Agreement shall be interpreted in accordance with the applicable exemptions from Section&nbsp;409A of the Code. If Executive and the Company determine that any payments or benefits payable under this Agreement intended to comply with Sections
409A(a)(2), (3) and (4)&nbsp;of the Code do not comply with Section&nbsp;409A of the Code, Executive and the Company agree to amend this Agreement, or take such other actions as Executive and the Company deem reasonably necessary or appropriate, to
comply with the requirements of Section&nbsp;409A of the Code and the Treasury Regulations thereunder (and any applicable transition relief) while preserving the economic agreement of the parties. To the extent that any provision in this Agreement
is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner that no payments payable under this Agreement shall be subject to an &#147;additional tax&#148; as defined in
Section&nbsp;409A(a)(1)(B) of the Code. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Any reimbursement of expenses or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits
payable under this Agreement shall be made in accordance with Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(1)(iv)</FONT> and shall be paid on or before the last day of Executive&#146;s taxable year following the
taxable year in which Executive incurred the expenses. The amount of expenses reimbursed or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits payable during any taxable year of Executive&#146;s shall not affect the amount eligible for
reimbursement or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits payable in any other taxable year of Executive&#146;s, and Executive&#146;s right to reimbursement for such amounts shall not be subject to liquidation or exchange for any
other benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature Page Follows) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement on September&nbsp;7, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>LUS</SMALL> T<SMALL>HERAPEUTICS</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc&nbsp;Hedrick</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Marc Hedrick, M.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:
Chief Executive Officer</P></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>E<SMALL>XECUTIVE</SMALL></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Norman LaFrance</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Print Name: Norman LaFrance,
M.D.</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE TO EMPLOYMENT AGREEMENT </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d151447dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plus Therapeutics Announces the Appointment of Industry Veteran, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Norman LaFrance, M.D., as the Company&#146;s Chief Medical Officer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>AUSTIN, Texas, September</B><B></B><B>&nbsp;13, 2021</B> &#150; <U>Plus Therapeutics, Inc</U>. (Nasdaq:&nbsp;<U>PSTV</U>) (the &#147;Company&#148;), a
clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancers, today announced the appointment of
Norman LaFrance, M.D. to the position of Chief Medical Officer and Senior Vice President. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are delighted to have Dr.&nbsp;LaFrance onboard as he
brings several decades of highly relevant clinical, regulatory and commercial expertise to the Plus Therapeutics management team,&#148; stated Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. &#147;His proven track
record in radiotherapeutics and drug development coupled with his commercial experience will be invaluable as we expand our pipeline, move key programs to late stage clinical development and best position the company for long-term regulatory and
commercial success.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;LaFrance&#146;s appointment begins on or around December&nbsp;8, 2021 and he joins the Company with nearly 40 years of
experience as a nuclear medicine physician and as an executive in the pharmaceutical and healthcare industries. Dr.&nbsp;LaFrance has a particular expertise in radiotherapeutic drug research and development as well as commercialization of molecular
imaging, diagnostic and therapeutic products. He was most recently Chief Medical Officer, Senior Vice President, at Jubilant Pharma Ltd, responsible for all Pharma Medical&nbsp;&amp; Regulatory Affairs activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am excited to join a company which reflects my passion to make an impact on patients with significant unmet medical needs,&#148; said Norman LaFrance,
M.D. &#147;From an industry perspective, it is clear that Plus Therapeutics&#146; focus on radiotherapeutics positions it firmly for long-term growth, and I am excited to lead development and expansion of its promising pipeline.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to Jubilant Pharma, Ltd., Dr.&nbsp;LaFrance served as Global Chief Medical Officer at IBA Molecular from 2010 to 2012, and as Senior Vice President,
Clinical Development and Chief Medical Officer at Molecular Insight Pharmaceuticals from 2007 to 2010. Prior to industry, Dr.&nbsp;LaFrance practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in
the departments of medicine and radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is Double Board Certified with Fellowship status both in internal medicine and nuclear medicine,
maintains active medical licensure in the U.S. along with active, professional society membership. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;LaFrance received his bachelor of science and
master of engineering degrees in nuclear engineering and science from Rensselaer Polytechnic Institute, and his medical degree from the University of Arizona, College of Medicine, Tucson. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Plus Therapeutics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated
radionuclides for several cancer targets. Central to the Company&#146;s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is
designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found
at&nbsp;<U>PlusTherapeutics.com</U> and <U>ReSPECT-Trials.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter Vozzo </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westwicke/ICR </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(443) <FONT STYLE="white-space:nowrap">377-4767</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peter.Vozzo@westwicke.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terri Clevenger </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westwicke/ICR </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(203) <FONT STYLE="white-space:nowrap">856-4326</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Terri.Clevenger@westwicke.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>pstv-20210907.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 9/13/2021 3:02:07 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:pstv="http://www.plustherapeutics.com/20210907"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"

  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.plustherapeutics.com/20210907"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />

    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20210907_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20210907_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pstv-20210907_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 9/13/2021 3:02:07 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pstv-20210907_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 9/13/2021 3:02:07 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pstv-20210907.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d151447d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pstv-20210907.xsd" xlink:type="simple"/>
    <context id="duration_2021-09-07_to_2021-09-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2021-09-07</startDate>
            <endDate>2021-09-07</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2021-09-07_to_2021-09-07"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2021-09-07_to_2021-09-07">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-09-07_to_2021-09-07"
      id="Hidden_dei_EntityCentralIndexKey">0001095981</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-09-07_to_2021-09-07">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-09-07_to_2021-09-07">2021-09-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-09-07_to_2021-09-07">PLUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-09-07_to_2021-09-07">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-09-07_to_2021-09-07">001-34375</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-09-07_to_2021-09-07">33-0827593</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-09-07_to_2021-09-07">4200 Marathon Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2021-09-07_to_2021-09-07">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-09-07_to_2021-09-07">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-09-07_to_2021-09-07">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-09-07_to_2021-09-07">78756</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-09-07_to_2021-09-07">(737)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-09-07_to_2021-09-07">255-7194</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-09-07_to_2021-09-07">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-09-07_to_2021-09-07">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-09-07_to_2021-09-07">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-09-07_to_2021-09-07">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-09-07_to_2021-09-07">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-09-07_to_2021-09-07">PSTV</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-09-07_to_2021-09-07">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139806368238408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 07, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001095981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  07,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLUS THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0827593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4200 Marathon Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(737)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-7194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PSTV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M44@T_0(\7PNAWAOZ/%S].V/R+U!+ P04    " !O.2U3GZ ;\+$"  #B#
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M#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
M   ( &\Y+5,<.&7J/P$  #P"   /    >&PO=V]R:V)O;VLN>&ULC5'+;L)
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !O.2U3!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M &\Y+5-N!6?,[0   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( &\Y+5.97)PC$ 8  )PG   3
M  "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ;SDM4XM=
M6IY,!   VA   !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( &\Y+5.?H!OPL0(  .(,   -
M  "  8X,  !X;"]S='EL97,N>&UL4$L! A0#%     @ ;SDM4Y>*NQS
M$P(   L              ( !:@\  %]R96QS+RYR96QS4$L! A0#%     @
M;SDM4QPX9>H_ 0  / (   \              ( !4Q   'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( &\Y+5,D'INBK0   /@!   :              "
M ;\1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &\Y
M+5-ED'F2&0$  ,\#   3              "  :02  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  .X3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d151447d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d151447d8k.htm">d151447d8k.htm</File>
    <File>d151447dex101.htm</File>
    <File>d151447dex991.htm</File>
    <File>pstv-20210907.xsd</File>
    <File>pstv-20210907_lab.xml</File>
    <File>pstv-20210907_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d151447d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d151447d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pstv-20210907_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pstv-20210907_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "pstv-20210907.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "pstv",
   "nsuri": "http://www.plustherapeutics.com/20210907",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d151447d8k.htm",
      "contextRef": "duration_2021-09-07_to_2021-09-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d151447d8k.htm",
      "contextRef": "duration_2021-09-07_to_2021-09-07",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.plustherapeutics.com//20210907/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-21-270847-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-270847-xbrl.zip
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MHJQ(I]*HF'GMMPLU[NW6,'NG,#K!SBE<O 3<%X#]>@%],4:; 9IO3G-C<5%
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MPX"!FZ$:M=.NQ0UP53_=AT#E0RQR,*Z9O2-I7ES(.+04,<7<C3EC+BQ[]NR
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M=50$+&(0[,5@J4)S>8K4;WG)N/S=7W[^$:5Y/$J6'."30TD^ 5("_C\VN8C
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MYW!(MX$20A&&]6-1,6%!<-9M/J?G41:5$%A63SJ56I4Y,7Z0HGTI\P^5>P+
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MO*[TF;9@5=J"$EI.61<"_0JA"@K7.P4[MP$[W%$>#3[2S.R(J40&W-ZJY77
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M*N!(N@OQ_!H@O$D\?;G-2_\N!P9/;WW+A>B*GF&6ZBC-N..74%HAI0J?N>,
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M,\E>T:2PX[<?WKS_XRUXICR+C/XU[$4#F[\_^@-^^?K\[9N]_P502P,$%
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M"L7>OG[3WMW9?O.K*!8P[RPP7T.S];T4^' Y^(R+X4]!_P=02P,$%     @
M;SDM4_1"T/I0 P  D@L  !$   !P<W1V+3(P,C$P.3 W+GAS9+U6;6_;-A#^
M7J#_X:9/&S")DHTVL!"GZ)8&")!FA9L.^U;0TMDF1I$:227QO]^1DFS9B=V\
M# M@A.;=<_?P7GWZX;Z2<(O&"JVF49:D$: J="G4<AHU-N:V$"+Z</;VS>E/
M<0SG%Y?7$,/*N=KFC-W=W27E0BBK9>/(@DT*73&(XU[_]YMO\&=K/8<92N06
MH>+6H8'?&B'+?)2.LO3]*$M&0YA![NU!R1WF,&'9F'E%&.?I*$]/X,MG^!2L
M*+@1%0ZANEX;L5PY^+GX!0+H7"N%4N(:+H3BJA!<PM>>\:]PJ8H$/DH),P^S
M1-.BN<4RZ:S>VS*WQ0HK_O8- ,5+V5R1R:::1CX071SNYT8FVBQ9Z0QSZQH9
M*<6DA484T0#Z8]P##"7"2^P&N.!V'D"]Q(<GC=,L'F<#7&W=[8ZS6C;6K=#P
M&NGY19NOD())>C( EB@VN$#08I$L]2TCP>.NO)9X_&&C-!TS*A)'L<<!1 KU
M]Q&$%\^I7H9.'D#NQ@&03283%J1[E$JW^X[.^CO6"H.V_W#GC)@W#B^TJ<YQ
MP1M)R$;]TW I%@++H$D%7*%R.SJ[&HZ;);IK7J&M>8$O"CX5W&-O)-H9^^OS
MU==0B]&9!P"$\A15K8V#MDJO=!&:YTAH_;>XSTCLK^)L1/E,R%@$ZE'V!]()
M[-5$^D2_B,BF2IY,Q!ZJ:7^(M\5]B,.Q?GAQ-/:;W\=BXF.1O7]2+!X,C_^
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M"EG<)RIY(4@K058*Z8%*@S8,3U1LO11W7*LM_14PV2Z:?A&*VO,_4$L#!!0
M   ( &\Y+5.B[1F]T 0  -\L   5    <'-T=BTR,#(Q,#DP-U]P<F4N>&UL
MU9KO<]HV&,??]Z[_@^:^V>YF_(.V6;B0'B-)CQM).*#;;F]ZPGX W63))XD
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M@]3T=8'9F+LY8C[,-E-=\@]02P$"% ,4    " !O.2U3'D,B-W$6   2?
M#@              @ $     9#$U,30T-V0X:RYH=&U02P$"% ,4    " !O
M.2U32#B56*\Y  "%\   $0              @ &=%@  9#$U,30T-V1E>#$P
M,2YH=&U02P$"% ,4    " !O.2U3ZYN^&\4(   1&@  $0
M@ %[4   9#$U,30T-V1E>#DY,2YH=&U02P$"% ,4    " !O.2U3]$+0^E #
M  "2"P  $0              @ %O60  <'-T=BTR,#(Q,#DP-RYX<V102P$"
M% ,4    " !O.2U3!$>Y\X0&  !)1P  %0              @ 'N7   <'-T
M=BTR,#(Q,#DP-U]L86(N>&UL4$L! A0#%     @ ;SDM4Z+M&;W0!   WRP
M !4              ( !I6,  '!S='8M,C R,3 Y,#=?<')E+GAM;%!+!08
1    !@ & '\!  "H:      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
